A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care
Awards and Recognition

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.

Sustainability

Guided by our values, our employees work every day to make meaningful differences in healthcare. At the core of what we do is our most valuable resource - our people. Learn more about us.

Leadership
Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.  

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.  

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Supporting healthcare transformation through the generation of real-world evidence.

Working closely with our members, we're developing products and services to solve your most complex challenges.

Our most recent insights, articles and more, all in one place.  

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Compelling stories from the front lines of America’s health systems.

The proactive, predictive and behind-the-scenes insights you need to stay ahead in healthcare delivered monthly to your inbox.

Statement on Senate Judiciary Committee Advancing Drug Pricing Bills

By Soumi Saha, Senior Vice President, Government Affairs, Premier Inc.

Today’s approval by the Senate Judiciary Committee of bills that support market competition and incentivize innovation in the pharmaceutical marketplace is an important step towards lowering drug prices. Federal actions to reduce the gaming of United States Patent and Trade Office (USPTO) and Food and Drug Administration (FDA) requirements or other attempts to unfairly delay competition by drug manufacturers are long overdue.

These bipartisan bills advance policies long advocated for by Premier to thwart anticompetitive practices, such as “product hopping,” “evergreening,” “pay for delay” and the filing of sham citizen petitions, that permit manufacturers to extend monopolies and block access to lower cost generic drugs and biosimilars. Premier is also pleased to see the Committee green light legislation that will improve collaboration across federal agencies to more effectively cultivate innovation while holding bad actors in the space accountable.

These policies align with recommendations that Premier submitted this week to the USPTO and FDA to address the rising cost of pharmaceuticals and help ensure that the patent system, while incentivizing innovation, does not unjustifiably delay generic drug and biosimilar competition. In our comments, Premier reflects on legislative barriers to innovating within our current healthcare system and opportunities for action to foster innovation, competition and affordability.

In many ways, these policies are low-hanging fruit as they have been addressed in a bipartisan and bicameral manner in prior Congressional sessions, but unfortunately never made it to the finish line. Now is the time to address these anticompetitive behaviors and help reduce the cost of drugs in the United States. Premier looks forward to working with Congress to pass these commonsense, bipartisan bills.

Login Register Change Registration